Company Profiles

driven by the PitchBook Platform

Moderna

Description

Developer of messenger RNA therapies. The company is developing an in vivo drug-modality platform that produces human proteins or antibodies inside patient cells, which are in turn secreted or active intracellularly. The platform is designed to address currently undruggable targets and to offer an alternative to existing drug modalities for a range of disease conditions. The platform has applications for inherited genetic disorders, hemophilic & blood factors and oncology.

2009

Founded

PRIVATE

Status

201-500

Employees

Series F

Latest Deal Type

$474M

Latest Deal Amount

$1.34B

Total Amount Raised

Description

Developer of messenger RNA therapies. The company is developing an in vivo drug-modality platform that produces human proteins or antibodies inside patient cells, which are in turn secreted or active intracellularly. The platform is designed to address currently undruggable targets and to offer an alternative to existing drug modalities for a range of disease conditions. The platform has applications for inherited genetic disorders, hemophilic & blood factors and oncology.

Website:

www.modernatx.com

Ownership Status

Privately held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Drug Delivery

Other Industries

Biotechnology

Primary Office

320 Bent Street Cambridge, MA 02141United States +1 (617) 714-6500
Request a free trial to the PitchBook Platform
You're viewing a free company profile from the PitchBook Platform. To explore Moderna's full profile, request a free trial.

Moderna Valuation and Funding

Request access
Deal TypeDateAmountRaised to DatePost-ValStatusStage

Moderna Cap Table

Stock# of Shares
Authorized
Par ValueDividend Rate (%)Original
Issue Price
LiquidationLiquidation
Pref. Multiple
Conversion
Price
% Owned

Moderna Investors (14)

Request access
Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
Seat
Contact
Info
Alexion PharmaceuticalsCorporationMinority000 0000000 0000
AstraZenecaCorporationMinority000 0000000 0000
BARDAOther000 0000000 0000
Bill & Melinda Gates FoundationVenture CapitalMinority000 0000000 0000
Boston Medical InvestorsVenture CapitalMinority000 0000000 0000
Alexion Pharmaceuticals Corporation
AstraZeneca Corporation
BARDA Other
Bill & Melinda Gates Foundation Venture Capital
Boston Medical Investors Venture Capital

Moderna Executive Team (26)

NameTitleBoard
Seat
Contact
Info
Stephane BancelChief Executive Officer, President & Board Member
Stephen Hoge MDPresident
Lorence Kim MDChief Financial Officer
Melissa Moore Ph.DChief Scientific Officer
Ipsita Roymoulik Ph.DDirector Analytical Development
Stephane Bancel Chief Executive Officer, President & Board Member
Stephen Hoge MD President
Lorence Kim MD Chief Financial Officer
Melissa Moore Ph.D Chief Scientific Officer
Ipsita Roymoulik Ph.D Director Analytical Development

Moderna Board Members (11)

NameRepresentingRoleSinceContact
Info
Elizabeth Nabel MDModernaBoard of Directors000 0000
Henri TermeerSelfBoard of Directors000 0000
John Mendlein Ph.DSelfBoard of Directors000 0000
Lee Babiss Ph.DSelfBoard of Directors000 0000
Noubar Afeyan Ph.DFlagship VenturesCo-Founder, Senior Managing Partner & Chief Executive Officer000 0000
Elizabeth Nabel MD Board of Directors Moderna
Henri Termeer Board of Directors Self
John Mendlein Ph.D Board of Directors Self
Lee Babiss Ph.D Board of Directors Self
Noubar Afeyan Ph.D Co-Founder, Senior Managing Partner & Chief Executive Officer Flagship Ventures
Request full access to PitchBook